Herbas VPB

Print
EN | LT
LT - Neutrofilų elastazės inhibitoriaus alvelestato panaudojimas kvėpavimo sistemos ligų, nulemtų alfa-1 antitripsino nepakankamumo, gydymui
EN - METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY

Legal status

Patent in force

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. A61K 31/444 (2006.01)
A61K 45/06 (2006.01)
A61P 11/00 (2006.01)
A61P 29/00 (2006.01)
European patent
(11) Number of the document 4106757
(13) Kind of document T
(96) European patent application number 21714345.2
Date of filing the European patent application 2021-03-16
(97) Date of publication of the European application 2022-12-28
(45) Date of publication and mention of the grant of the patent 2023-08-23
(46) Date of publication of the claims translation 2023-11-10
PCT application
(86) Number PCT/GB2021/050653
Date 2021-03-16
PCT application publication
(87) Number WO 2021/209739
Date 2021-10-21
Priority applications
(30) Number Date Country code
202005519 2020-04-16 GB
202005520 2020-04-16 GB
202062706195 P 2020-08-04 US
Inventors
(72)
PARKIN, Jacqueline , GB
Grantee
(73) Mereo Biopharma 4 Limited , 1 Cavendish Place, London Greater London W1G 0QF, GB
Attorney or representative
(74) Jurga PETNIŪNAITĖ, AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius, LT
Title
(54) Neutrofilų elastazės inhibitoriaus alvelestato panaudojimas kvėpavimo sistemos ligų, nulemtų alfa-1 antitripsino nepakankamumo, gydymui
  METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY
Last renewal fee
Payment date Validity (years) Amount
2025-01-21 5 115.00 EUR
Next renewal fee
2026-03-16